Matching articles for "cephalosporins"
Issue 1750 · March 16, 2026
Two New Drugs for Gonorrhea

The FDA has approved two antibiotics, gepotidacin ( Blujepa — GSK) and zoliflodacin ( Nuzolvence — Entasis), for oral treatment of uncomplicated urogenital gonorrhea in patients ≥12 years old.…

Med Lett Drugs Ther. 2026 Mar 16; 68(1750):41-3 doi:10.58347/tml.2026.1750a
The FDA has approved two antibiotics, gepotidacin ( Blujepa — GSK) and zoliflodacin ( Nuzolvence — Entasis), for oral treatment of uncomplicated urogenital gonorrhea in patients ≥12 years old. Gepotidacin is approved for use in persons weighing ≥45 kg who have limited or no alternative treatment options; it was approved in 2025 for treatment of uncomplicated urinary tract infection in females. Zoliflodacin is approved for use in persons weighing ≥35 kg. Neither drug is indicated for treatment of rectal or pharyngeal gonorrhea.
Issue 1707 · July 22, 2024
Cefepime/Enmetazobactam (Exblifep) for Complicated Urinary Tract Infections

The FDA has approved Exblifep (Allecra), a fixed-dose combination of the cephalosporin cefepime and the beta-lactamase inhibitor enmetazobactam, for IV treatment of adults with complicated urinary tract…

Med Lett Drugs Ther. 2024 Jul 22; 66(1707):117-8 doi:10.58347/tml.2024.1707d
The FDA has approved Exblifep (Allecra), a fixed-dose combination of the cephalosporin cefepime and the beta-lactamase inhibitor enmetazobactam, for IV treatment of adults with complicated urinary tract infections (cUTIs), including pyelonephritis, caused by designated susceptible microorganisms (see Spectrum of Activity). Exblifep is the first product that contains enmetazobactam to be approved in the US.
Issue 1623 · May 3, 2021 Free
In Brief: New Recommendations for Gonococcal Infection

The CDC has issued new recommendations for treatment of gonococcal infection. A single 500-mg IM dose (1000 mg in patients weighing ≥150 kg) of the third-generation cephalosporin ceftriaxone is now the…

Med Lett Drugs Ther. 2021 May 3; 63(1623):72
The CDC has issued new recommendations for treatment of gonococcal infection. A single 500-mg IM dose (1000 mg in patients weighing ≥150 kg) of the third-generation cephalosporin ceftriaxone is now the treatment of choice for patients with uncomplicated urogenital, rectal, or pharyngeal gonorrhea.
Issue 1559 · November 5, 2018
Plazomicin (Zemdri) - A New Aminoglycoside Antibiotic

The FDA has approved the new aminoglycoside antibiotic plazomicin ( Zemdri – Achaogen) for IV treatment of adults with complicated urinary tract infections (cUTIs). Plazomicin is active against multi-drug-…

Med Lett Drugs Ther. 2018 Nov 5; 60(1559):180-2
The FDA has approved the new aminoglycoside antibiotic plazomicin ( Zemdri – Achaogen) for IV treatment of adults with complicated urinary tract infections (cUTIs). Plazomicin is active against multi-drug- resistant Enterobacteriaceae, including strains resistant to other aminoglycosides.
Issue 1532 · October 23, 2017
Drugs for Common Bacterial Infections in Adults

Bacterial infections in adults are generally treated empirically, with the antibiotic covering most, but not all, of the potential causative pathogens. For some infections, culture and sensitivity testing can…

Med Lett Drugs Ther. 2017 Oct 23; 59(1532):171-7
Bacterial infections in adults are generally treated empirically, with the antibiotic covering most, but not all, of the potential causative pathogens. For some infections, culture and sensitivity testing can guide treatment, allowing for use of narrower-spectrum antibiotics. The recommended dosages and durations of antibiotic treatment for common respiratory, skin, and urinary tract infections are listed in Tables 1-3. Infectious disease experts now recommend shorter treatment durations for many infections to reduce the development of antimicrobial resistance and minimize adverse effects.
Issue 1496 · June 6, 2016
Alternatives to Fluoroquinolones

The FDA has announced that it is requiring changes in the labeling of systemic fluoroquinolones to warn that the risk of serious adverse effects, including tendinitis, peripheral neuropathy and CNS effects,…

Med Lett Drugs Ther. 2016 Jun 6; 58(1496):75-6
The FDA has announced that it is requiring changes in the labeling of systemic fluoroquinolones to warn that the risk of serious adverse effects, including tendinitis, peripheral neuropathy and CNS effects, generally outweighs their benefit for the treatment of acute sinusitis, acute exacerbations of chronic bronchitis, and uncomplicated urinary tract infections. For these infections, the new labels will recommend reserving fluoroquinolones for patients with no other treatment options.
Issue 1469 · May 25, 2015
Ceftazidime/Avibactam (Avycaz) - A New Intravenous Antibiotic

The FDA has approved ceftazidime/avibactam ( Avycaz – Actavis) for IV treatment of complicated urinary tract and intra-abdominal infections in adults who have limited or no other treatment options.…

Med Lett Drugs Ther. 2015 May 25; 57(1469):79-80
The FDA has approved ceftazidime/avibactam ( Avycaz – Actavis) for IV treatment of complicated urinary tract and intra-abdominal infections in adults who have limited or no other treatment options. Ceftolozane/tazobactam ( Zerbaxa – Cubist), another cephalosporin/beta-lactamase inhibitor combination, was approved in 2014.
Issue 1463 · March 2, 2015
Ceftolozane/Tazobactam (Zerbaxa) - A New Intravenous Antibiotic

The FDA has approved ceftolozane/tazobactam ( Zerbaxa – Cubist), a combination of a new cephalosporin antibiotic and a beta-lactamase inhibitor, for intravenous treatment of complicated urinary tract and…

Med Lett Drugs Ther. 2015 Mar 2; 57(1463):31-3
The FDA has approved ceftolozane/tazobactam ( Zerbaxa – Cubist), a combination of a new cephalosporin antibiotic and a beta-lactamase inhibitor, for intravenous treatment of complicated urinary tract and intra-abdominal infections in adults.
Issue 1410 · February 18, 2013 Free
Addendum: Cephalosporins for Patients with Penicillin Allergy

A reader who took the online continuing medical education (CME) exam for issue 1406 ( Med Lett Drugs Ther 2012; 54:101 ) pointed out that the first question assumed that a rash following oral administration of…

Med Lett Drugs Ther. 2013 Feb 18; 55(1410):16
A reader who took the online continuing medical education (CME) exam for issue 1406 ( Med Lett Drugs Ther 2012; 54:101 ) pointed out that the first question assumed that a rash following oral administration of ampicillin would be due to allergy. Perhaps we should have mentioned in our article on penicillin allergy that late-appearing maculopapular rashes associated with oral ampicillin or amoxicillin are generally considered non-allergic and need not preclude subsequent administration of ampicillin or amoxicillin.
Issue 1406 · December 24, 2012
Cephalosporins for Patients with Penicillin Allergy

Only a small minority of patients who say they are allergic to penicillin will have a reaction if they take a penicillin.

Med Lett Drugs Ther. 2012 Dec 24; 54(1406):101
Only a small minority of patients who say they are allergic to penicillin will have a reaction if they take a penicillin.
Issue 1358 · February 21, 2011
Treatment of Clostridium Difficile Infection

Clostridium difficile infection (CDI) is the most common infectious cause of healthcare-associated diarrhea in adults. The incidence and severity of CDI have increased in recent years with the emergence of an…

Med Lett Drugs Ther. 2011 Feb 21; 53(1358):14-6
Clostridium difficile infection (CDI) is the most common infectious cause of healthcare-associated diarrhea in adults. The incidence and severity of CDI have increased in recent years with the emergence of an epidemic virulent strain (NAP1/BI/027). Common risk factors include admission to a healthcare facility, increasing age and severity of underlying illness, gastric acid suppression and exposure to antimicrobials, particularly clindamycin, ampicillin, cephalosporins or fluoroquinolones. Patients who develop CDI while receiving a precipitating antibiotic should have the antibiotic discontinued, if possible, or switched to another appropriate antimicrobial with a lower risk of CDI.
Issue 94 · June 1, 2010
Drugs for Bacterial Infections

The text below reviews some common bacterial infections and their treatment. The recommendations made here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter…

Treat Guidel Med Lett. 2010 Jun; 8(94):43-52
The text below reviews some common bacterial infections and their treatment. The recommendations made here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter consultants.
Issue 1320 · September 7, 2009 Free
Addendum: Why Not Ertapenem for Surgical Prophylaxis?

Some readers have asked why the June 2009 issue of Treatment Guidelines (Antimicrobial Prophylaxis for Surgery) did not recommend use of ertapenem (Invanz) for prevention of infection after elective colorectal…

Med Lett Drugs Ther. 2009 Sep 7; 51(1320):72
Some readers have asked why the June 2009 issue of Treatment Guidelines (Antimicrobial Prophylaxis for Surgery) did not recommend use of ertapenem (Invanz) for prevention of infection after elective colorectal surgery. Ertapenem is a broad-spectrum carbapenem that has been approved for such use by the FDA. Medical Letter consultants do not recommend use of broad-spectrum drugs such as ertapenem, third-generation cephalosporins such as cefotaxime (Claforan) , ceftriaxone (Rocephin) , cefoperazone (Cefobid) , ceftazidime ( Fortaz , and others) or ceftizoxime (Cefizox) , or fourth-generation cephalosporins such as cefepime (Maxipime) for routine surgical prophylaxis because they are expensive, some are less active than first- or second-generation cephalosporins against staphylococci, and their spectrum of activity includes organisms rarely encountered in elective surgery. These drugs should be reserved for treatment of serious infections, particularly those likely to be caused by organisms resistant to other antimicrobials.
Issue 82 · June 1, 2009
Antimicrobial Prophylaxis for Surgery

Antimicrobial prophylaxis can decrease the incidence of infection, particularly surgical site infection, after certain procedures. Recommendations for prevention of surgical site infection are listed in the…

Treat Guidel Med Lett. 2009 Jun; 7(82):47-52
Antimicrobial prophylaxis can decrease the incidence of infection, particularly surgical site infection, after certain procedures. Recommendations for prevention of surgical site infection are listed in the table that begins on page 48. Antimicrobial prophylaxis for dental procedures to prevent endocarditis is discussed in The Medical Letter 2007; 49:99 .
Issue 1301 · December 15, 2008 Free
Drugs That May Cause Psychiatric Symptoms

Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness,…

Med Lett Drugs Ther. 2008 Dec 15; 50(1301):100-3
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression. Click here to view the free full article.
Issue 1266 · July 30, 2007
Drugs for Community-Acquired Bacterial Pneumonia

Most patients with community-acquired pneumonia (CAP) are treated empirically. New guidelines published jointly by the Infectious Diseases Society of America and the American Thoracic Society have recently…

Med Lett Drugs Ther. 2007 Jul 30; 49(1266):62-4
Most patients with community-acquired pneumonia (CAP) are treated empirically. New guidelines published jointly by the Infectious Diseases Society of America and the American Thoracic Society have recently become available.
Issue 57 · May 1, 2007
Choice of Antibacterial Drugs

Information about empirical treatment of bacterial infections, emerging trends in antimicrobial resistance, new drugs and new data about older drugs continue to become available. Usual pathogens and empiric…

Treat Guidel Med Lett. 2007 May; 5(57):33-50
Information about empirical treatment of bacterial infections, emerging trends in antimicrobial resistance, new drugs and new data about older drugs continue to become available. Usual pathogens and empiric treatment for some common types of infections are summarized in the text and a table listing the drugs of choice and alternatives for each pathogen begins on page 40. The recommendations made here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter consultants.
Issue 1189 · August 16, 2004
Telithromycin (Ketek) for Respiratory Infections

Telithromycin ( Ketek - Aventis) has been approved by the FDA for oral treatment of mild to moderate community-acquired pneumonia, acute exacerbations of chronic bronchitis and acute bacterial sinusitis in…

Med Lett Drugs Ther. 2004 Aug 16; 46(1189):66-8
Telithromycin ( Ketek - Aventis) has been approved by the FDA for oral treatment of mild to moderate community-acquired pneumonia, acute exacerbations of chronic bronchitis and acute bacterial sinusitis in patients age 18 and older. The drug is the first in a new class of antibiotics, the ketolides, derived from the macrolide erythromycin. Telithromycin has been marketed in Europe since 2001.
Issue 19 · March 1, 2004
Choice of Antibacterial Drugs

New drugs for bacterial infections and new information about older drugs continue to become available. Empirical treatment of some common bacterial infections is discussed in this article. A table listing the…

Treat Guidel Med Lett. 2004 Mar; 2(19):13-22
New drugs for bacterial infections and new information about older drugs continue to become available. Empirical treatment of some common bacterial infections is discussed in this article. A table listing the drugs of choice and alternatives for each pathogen begins on page 18. These recommendations are based on results of susceptibility studies, clinical trials and the opinions of Medical Letter consultants. Local resistance patterns should be taken into account. Trade names are listed on page 24.
Issue 1175 · February 2, 2004
Daptomycin (Cubicin) for Skin and Soft Tissue Infections

Daptomycin ( Cubicin - Cubist), a cyclic lipopeptide (a new class of antibiotics), has been approved by the FDA for intravenous (IV) treatment of complicated skin and skin structure infections. It is being…

Med Lett Drugs Ther. 2004 Feb 2; 46(1175):11-2
Daptomycin ( Cubicin - Cubist), a cyclic lipopeptide (a new class of antibiotics), has been approved by the FDA for intravenous (IV) treatment of complicated skin and skin structure infections. It is being promoted as a once-daily bactericidal alternative to vancomycin ( Vancocin , and others) for methicillin-resistant Staphylococcus aureusinfections.
Issue 13 · September 1, 2003
Drugs for Pneumonia

The choice of drugs for treatment of pneumonia depends on the most likely pathogens causing the infection and local antimicrobial resistance patterns. Factors such as severity of illness, presence of co-morbid…

Treat Guidel Med Lett. 2003 Sep; 1(13):83-8
The choice of drugs for treatment of pneumonia depends on the most likely pathogens causing the infection and local antimicrobial resistance patterns. Factors such as severity of illness, presence of co-morbid conditions and whether the infection is community or hospital-acquired also need to be considered.
Issue 1144 · November 25, 2002
Hemolysis From Ceftriaxone

Immune-mediated hemolysis is a rare adverse effect of second- and third-generation cephalosporins, especially cefotetan (Cefotan) (PA Arndt et al, Transfusion 1999; 39:1239). A recent report serves as a…

Med Lett Drugs Ther. 2002 Nov 25; 44(1144):100-1
Immune-mediated hemolysis is a rare adverse effect of second- and third-generation cephalosporins, especially cefotetan (Cefotan) (PA Arndt et al, Transfusion 1999; 39:1239). A recent report serves as a reminder that life-threatening immune-mediated hemolysis rarely can follow administration of ceftriaxone (Rocephin) , one of the most commonly used parenteral antibiotics in the US (A Citak et al, J Paediatr Child Health 2002; 38:209).
Issue 1134 · July 8, 2002
Drugs That May Cause Psychiatric Symptoms

Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment may also be due to the underlying illness, previously…

Med Lett Drugs Ther. 2002 Jul 8; 44(1134):59-62
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment may also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression.
Issue 1122 · January 21, 2002
Cefditoren (Spectracef) - A New Oral Cephalosporin

Cefditoren pivoxil ( Spectracef — TAP), a new oral third-generation cephalosporin, has been approved by the FDA for treatment of acute exacerbations of chronic bronchitis, pharyngitis, tonsillitis and…

Med Lett Drugs Ther. 2002 Jan 21; 44(1122):5-6
Cefditoren pivoxil ( Spectracef — TAP), a new oral third-generation cephalosporin, has been approved by the FDA for treatment of acute exacerbations of chronic bronchitis, pharyngitis, tonsillitis and uncomplicated skin and soft tissue infections in adults and children 12 or more years old. The drug has been used in Japan for 7 years.
Issue 1034 · August 28, 1998
Cefdinir--A New Oral Cephalosporin

Cefdinir ( Omnicef - Parke-Davis), a third-generation oral cephalosporin, has been approved by the FDA for treatment of acute sinusitis, otitis media, acute exacerbations of chronic bronchitis, pharyngitis,…

Med Lett Drugs Ther. 1998 Aug 28; 40(1034):85-7
Cefdinir ( Omnicef - Parke-Davis), a third-generation oral cephalosporin, has been approved by the FDA for treatment of acute sinusitis, otitis media, acute exacerbations of chronic bronchitis, pharyngitis, community-acquired pneumonia and skin infections. Other drugs available for these indications are reviewed in The Medical Letter Handbook of Antimicrobial Therapy , 1998.
Issue 983 · September 13, 1996
Cefepime (Maxipime) - A New Parenteral Cephalosporin

Cefepime hydrochloride ( Maxipime - Bristol-Myers Squibb), a new 'fourth-generation' cephalosporin, has been approved by the US Food and Drug Administration (FDA) for parenteral treatment of urinary tract…

Med Lett Drugs Ther. 1996 Sep 13; 38(983):84-5
Cefepime hydrochloride ( Maxipime - Bristol-Myers Squibb), a new 'fourth-generation' cephalosporin, has been approved by the US Food and Drug Administration (FDA) for parenteral treatment of urinary tract infections and skin and skin-structure infections due to susceptible pathogens, and for moderate to severe pneunmonia caused by Streptococcus pneumoniae (pneumococci), Pseudomonas aeruginosa, Enterobacter or Klebsiella pneumoniae.
Issue 970 · March 15, 1996
Ceftibuten - A New Oral Cephalosporin

Ceftibuten (Cedax - Schering), an oral cephalosporin similar to cefixime (Suprax - Medical Letter, 31:73, 1989), has been approved by the US Food and Drug Administration (FDA) for treatment of acute otitis…

Med Lett Drugs Ther. 1996 Mar 15; 38(970):23-4
Ceftibuten (Cedax - Schering), an oral cephalosporin similar to cefixime (Suprax - Medical Letter, 31:73, 1989), has been approved by the US Food and Drug Administration (FDA) for treatment of acute otitis media, pharyngitis or tonsillitis, and for acute bacterial exacerbations of chronic bronchitis.
Issue 884 · November 27, 1992
Cefpodoxime Proxetil - A New Oral Cephalosporin

Cefpodoxime proxetil ( Vantin - Upjohn), a new third-generation oral cephalosporin, has been approved for marketing by the US Food and Drug Administration. It is available for twice-daily treatment of…

Med Lett Drugs Ther. 1992 Nov 27; 34(884):107-8
Cefpodoxime proxetil ( Vantin - Upjohn), a new third-generation oral cephalosporin, has been approved for marketing by the US Food and Drug Administration. It is available for twice-daily treatment of pharyngitis, upper and lower respiratory infections, otitis media, urinary tract infections, skin and soft tissue infections, and for single-dose treatment of uncomplicated gonorrhea in men or women and anorectal gonorrhea in women.
Issue 879 · September 18, 1992
Loracarbef

Loracarbef ( Lorabid - Lilly), a new beta-lactam antibiotic with antimicrobial activity similar to the second-generation cephalosporins, has been approved by the US Food and Drug Administration for treatment…

Med Lett Drugs Ther. 1992 Sep 18; 34(879):87-8
Loracarbef ( Lorabid - Lilly), a new beta-lactam antibiotic with antimicrobial activity similar to the second-generation cephalosporins, has been approved by the US Food and Drug Administration for treatment of respiratory, skin, and urinary tract infection caused by susceptible organisms in both adults and children. It will probably compete with drugs such as trimethoprim-sulfamethoxazole ( Bactrim , Septra , and others), amoxicillin-clavulanic acid ( Augmentin ), cefaclor ( Ceclor ), cefuroxime axetil ( Ceftin ), and cefprozil ( Cefzil - Medical Letter, 34:63, 1992).
Issue 873 · June 26, 1992
Cefprozil

Cefprozil ( Cefzil - Bristol-Myers Squibb), a new oral second-generation cephalosporin, was recently released in the USA for treatment of pharyngitis, bronchitis, otitis media, and skin and skin-structure…

Med Lett Drugs Ther. 1992 Jun 26; 34(873):63-4
Cefprozil ( Cefzil - Bristol-Myers Squibb), a new oral second-generation cephalosporin, was recently released in the USA for treatment of pharyngitis, bronchitis, otitis media, and skin and skin-structure infections.
Issue 850 · August 9, 1991
Intravenous Ciprofloxacin

Ciprofloxacin, previously available orally ( Cipro - Medical Letter, 30:11, 1988) and for ophthalmic use ( Ciloxan - Medical Letter, 33:52, May 31, 1991), is now the first fluoroquinolone antibiotic to become…

Med Lett Drugs Ther. 1991 Aug 9; 33(850):75-6
Ciprofloxacin, previously available orally ( Cipro - Medical Letter, 30:11, 1988) and for ophthalmic use ( Ciloxan - Medical Letter, 33:52, May 31, 1991), is now the first fluoroquinolone antibiotic to become available in the USA in an intravenous (IV) formulation. Cipro I.V. (Miles) is being promoted as an alternative to third-generation cephalosporins, aminoglycosides, and other drugs used for treatment of serious infections.
Issue 832 · November 30, 1990
Choice of Cephalosporin

Since the last Medical Letter review of cephalosporin antibiotics (volume 25, page 57, 1983), many new cephalosporins have become available in the USA.

Med Lett Drugs Ther. 1990 Nov 30; 32(832):107-10
Since the last Medical Letter review of cephalosporin antibiotics (volume 25, page 57, 1983), many new cephalosporins have become available in the USA.
Issue 822 · July 13, 1990
Cefmetazole Sodium (Zefazone)

Cefmetazole sodium ( Zefazone - Upjohn), a second-generation parenteral cephalosporin, was recently marketed in the USA for intravenous (IV) treatment of various infections caused by susceptible organisms.…

Med Lett Drugs Ther. 1990 Jul 13; 32(822):65-6
Cefmetazole sodium ( Zefazone - Upjohn), a second-generation parenteral cephalosporin, was recently marketed in the USA for intravenous (IV) treatment of various infections caused by susceptible organisms. Like cefotetan ( Cefotan ), cefamandole ( Mandol ), cefoperazone ( Cefobid ), and moxalactam ( Moxam ), cefmetazole contains a methylthiotetrazole group that has been associated with prothrombin deficiency.
Issue 803 · October 20, 1989
Treatment of Clostridium Difficile Diarrhea

The gram-positive bacillus Clostridium difficile is the most common identifiable cause of antibiotic-associated diarrhea and pseudomembranous colitis (R Fekety in GL Mandell et al, eds, Principles and Practice…

Med Lett Drugs Ther. 1989 Oct 20; 31(803):94-5
The gram-positive bacillus Clostridium difficile is the most common identifiable cause of antibiotic-associated diarrhea and pseudomembranous colitis (R Fekety in GL Mandell et al, eds, Principles and Practice of Infectious Diseases , 3rd ed, New York:Churchill Livingstone, 1990, page 863). C. difficile colitis usually develops during or soon after antibiotic treatment. Virtually any antimicrobial agent can cause the disorder, but clindamycin, ampicillin and the cephalosporins have been implicated most frequently. Pseudomembranous colitis was recently reported in five patients who had each taken only a single dose of a cephalosporin (JP Freiman et al, JAMA, 262:902, August 18, 1989).
Issue 798 · August 11, 1989
Cefixime - A New Oral Cephalosporin

Cefixime ( Suprax - Lederle), an oral cephalosporin antibiotic, was recently approved for marketing by the US Food and Drug Administration. Claimed to be the first oral third-generation cephalosporin, the new…

Med Lett Drugs Ther. 1989 Aug 11; 31(798):73-5
Cefixime ( Suprax - Lederle), an oral cephalosporin antibiotic, was recently approved for marketing by the US Food and Drug Administration. Claimed to be the first oral third-generation cephalosporin, the new drug is offered for once-a-day treatment of otitis media, pharyngitis, bronchitis and urinary tract infections.
Issue 794 · June 16, 1989
Treatment of Lyme Disease

Lyme disease, a multisystem bacterial transmitted by Ixodid ticks, particularly in early summer, continues to be a common problem in the USA and many other countries. Since last year (Medical Letter, 30:65,…

Med Lett Drugs Ther. 1989 Jun 16; 31(794):57-9
Lyme disease, a multisystem bacterial transmitted by Ixodid ticks, particularly in early summer, continues to be a common problem in the USA and many other countries. Since last year (Medical Letter, 30:65, 1988), some new information has become available, but data on the choice, dosage and duration of antibiotic therapy are still available, but data on the choice, dosage and duration of antibiotic therapy are still limited.
Issue 772 · August 12, 1988
Penicillin Allergy

A penicillin is the drug of choice for treatment of many infections, but allergic reactions to these drugs occur frequently and, rarely, can be fatal. From 5% to 20% of patients have a history of a rash or…

Med Lett Drugs Ther. 1988 Aug 12; 30(772):79-80
A penicillin is the drug of choice for treatment of many infections, but allergic reactions to these drugs occur frequently and, rarely, can be fatal. From 5% to 20% of patients have a history of a rash or some other reaction while taking a penicillin, but maculopapular rashes with ampicillin or amoxicillin, especially in children with infectious mononucleosis, are probably not allergic.
Issue 769 · July 1, 1988
Treatment Lyme Disease

Lyme Disease, a multisystem inflammatory disorder transmitted by lxodid ticks and caused by the spirochete Borrelia burgdorferi , is now the most common tick-transmitted illness in the USA. It has been…

Med Lett Drugs Ther. 1988 Jul 1; 30(769):65-6
Lyme Disease, a multisystem inflammatory disorder transmitted by lxodid ticks and caused by the spirochete Borrelia burgdorferi , is now the most common tick-transmitted illness in the USA. It has been reported in 32 states and on all other continents except Antarctica. Infected ticks have been found not only in wooded areas, but also on well-maintained suburban lawns (RC Falco and D Fish, Am J Epidemiol, 127:826, April 1988). Optimal treatment for this newly discovered disease is still being determined, but some recommendations based on published experience and work in progress can be made.
Issue 767 · June 3, 1988
Cefuroxime Axetil

Cefuroxime axetil ( Ceftin - Glaxo), an oral form of the second-generation parenteral cephalosporin cefuroxime ( Zinacef ), was recently marketed in the USA. Previously available oral cephalosporins are the…

Med Lett Drugs Ther. 1988 Jun 3; 30(767):57-9
Cefuroxime axetil ( Ceftin - Glaxo), an oral form of the second-generation parenteral cephalosporin cefuroxime ( Zinacef ), was recently marketed in the USA. Previously available oral cephalosporins are the first-generation drugs cephalexin ( Keflex ; and others), cephradine ( Anspor ; and others) and cefadroxil ( Duricef ; and others), and the second-generation cefaclor ( Ceclor ); second-generation cephalosporins have more activity against gram-negative bacteria.
Issue 758 · January 29, 1988
Ciprofloxacin

Ciprofloxacin hydrochloride ( Cipro - Miles), a synthetic antibacterial agent, was recently marketed in the USA for oral treatment of a wide variety of infections. Ciprofloxacin is the second fluoroquinolone…

Med Lett Drugs Ther. 1988 Jan 29; 30(758):11-3
Ciprofloxacin hydrochloride ( Cipro - Miles), a synthetic antibacterial agent, was recently marketed in the USA for oral treatment of a wide variety of infections. Ciprofloxacin is the second fluoroquinolone to become available in this country; norfloxacin ( Noroxin - Medical Letter, 29:25, 1987) is marketed only for treatment of urinary tract infections. Fluoroquinolones are more potent and have a much broader spectrum of activity than older quinolones such as nalidixic acid ( NegGram ).